Posted by AGORACOM
at 10:24 AM on Thursday, August 26th, 2021
VSBLTY Groupe Technologies (CSE:VSBY / OTC:VSBGF) is a disruptive computer vision software company that is using A.I. and Machine Learning to transform the retail and security industries.
$VSBY Teaches Computers How to Interpret Surroundings. For example, detecting anomalies better than any human ever can
$VSBY Then Delivers the Context of Their Surroundings via Alerts, so that humans can make decisions and act on then faster than ever possible
$VSBY technology serves the dual function of both monitoring (i.e. a stadium, a store) and marketing (serving ads based on real-time demographics)
In March, the company signed a major deal with Grupo Modelo (part of the AB InBev family of companies) and Retailigent to jointly create an international digital in-store media network.
And in June, VSBLTY raised $9.78 million in funding, putting the company on a path to profitability.
Now, VSBLTY CEO Jay Hutton has provided a corporate update, detailing that:
Q2 yielded strong billings growth, at 165% over Q1
A total of $4.1 million USD in new contracts
And accelerated growth, as the company gains “deployment momentum.”
We sat down with the chief executive, for a deeper dive into the state of play…
Posted by AGORACOM-JC
at 4:40 PM on Wednesday, August 25th, 2021
Alejandro Antalich, CEO of Biomind. “We, both, are driven by innovation. At Biomind, our objective is to change the course of medicine by assisting doctors in potentially saving more lives and providing a better quality of life to millions of people suffering from addiction, chronic pain, depression, anxiety, and other mental health disorders.
Biomind Labs is Developing the next generation of medicines for the 21st century … the pharmaceutical side of psychedelics
THE PROBLEM
● Depression and anxiety cost the global economy US$ 1 trillion each year
~ 20% of the world’s children and adolescents have a mental health condition
Suicide is the second leading cause of death among 15-29 year-olds
13% rise in mental health conditions & substance use disorders in last decade (to 2017)
Mental health conditions now cause 1 in 5 years lived with disability
#Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety and depression amongst other things
More than 80% of the global population prefers natural products as sources of new drug candidates …
and that is good because Biomind’s vertical integration approach – Transforming natural psychotropic compounds into pharmaceuticals – creating drug therapies that harness the medicinal power of natural psychedelic compounds
1 indication is already in Phase 2 … 3 indications in Phase 2 by end 2021 … 3 in Phase 3 by end 2022.
Sit back, relax and watch this powerful interview with Alejandro Antalich, Chief Executive Officer of Biomind Labs.
Posted by AGORACOM-JC
at 4:05 PM on Tuesday, August 24th, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing high value-added silicon products that are sought after by battery and electric vehicle manufacturers – but nobody has yet delivered – until now.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
As such, HPQ firmly believes its silicon products will play an important role in the renewable energy revolution. To this end, the Company had also announced some small but important initiatives in Hydrogen power generation over the last 12 months … but that initiative was significantly accelerated today when HPQ announced HPQ Launches Revolutionary and Breakthrough Green Hydrogen Extraction Technology Venture
How much acceleration? Try “SCALABLE WITH NO LIMITS”
“EBH2 is scalable with no limits. It can power a small domestic generator up to ships, factories, buildings, cryptocurrency mines with high energy consumption and even cities.”
EBH2 believes it can scale to power the planned high purity silicon and Nano silicon production by HPQ. If successful, HPQ proposes to bundle the energy production capability of EBH2 systems with its silicon production to further reduce the environmental footprint of its developing high purity silicon, nano powders, and other Renewable Energy products. Moreover, if successful, EBH2 would provide HPQ with “power plant” capabilities that would allow it to produce its products anywhere on the planet.
If that wasn’t enough HPQ added the following:
“all the while opening up new, and massive addressable markets for a system that can produce cheaply green hydrogen, on demand …. The Agreement establishes the terms of the creation of a new Joint venture Company (“NEWCO”) owned by HPQ and EBH2 that will market, sell and service EBH2 systems and products in North America (Canada, Mexico, and the United States). …. units could readily replace solar panels or standby generators for homeowners.”
Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!
Posted by AGORACOM-JC
at 4:03 PM on Tuesday, August 24th, 2021
Kidoz owns the biggest mobile advertising platform for kids and families. How big? There are almost 4,000 apps around the world using Kidoz, reaching over 300 MILLION kids. The company works with top brands, including Disney, McDonald’s, Hasbro, and Lego, and is a trusted partner of Apple and Google.
We sat down with Kidoz Inc. Co-CEOs Jason Williams & Eldad Ben Tora to discuss their stunning Q2 growth, and more.
Q2 2021 highlights include:
Total Revenue of $2,177,505 – growth of 196% compared to Q2 2020 Total Revenue of $736,827.
AdTech revenue of $2,120,500 – growth of 247% compared to Q2 2020 AdTech Revenue $611,709.
Gross Profit of $1,024,333 – growth of 214% compared to Q2 2020 Gross Profit of $325,769.
EBITDA of $48,079 a 124% improvement from an EBITDA loss of ($197,057) in Q2 2020.
Sit back, relax and watch this powerful interview.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison talk about the relationship between psychedelics and psychosis and discuss the abuse potential of ketamine.
Amirah Al Idrus explores the regulatory issues facing psychedelics, the setting in which they’re administered and how traditional business models may need to evolve in the process. At Novamind, we’re building the infrastructure to expand access to psychedelics in anticipation of their FDA approval. We’ve developed and are developing psychedelic therapy protocols to target difficult-to-treat mental health conditions that are underserved by the current standard of care. You can learn more about those treatment protocols here.
We know ketamine’s power to treat depression. “Within hours, a single dose of the psychedelic substance has been shown to curb suicidal intent, and recent clinical trials suggest these effects work on two thirds of patients, lasting for up to several weeks before fading away.” But recent results are getting us closer to the scientific reason why—ketamine may be responsible for decreasing the release of glutamate in our brains.
Posted by AGORACOM-JC
at 4:01 PM on Wednesday, August 18th, 2021
Liquid Avatar Technologies (LQID: CSE) (LQAVF: OTCQB) is a global blockchain, personal identity & Fintech solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified Self Sovereign Identity (“SSI”) through its Liquid Avatar platform (www.liquidavatar.com)
GENERALLY – Liquid Avatar Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.
SPECIFICALLY – Liquid Avatar Specializes In
Continuous Online Identity Verification
Personal Identity Management
Personal Data Monetization.
The LAVCE (Liquid Avatar Credentials Ecosystem) currently supports verifiable credentials by creating a Trust Triangle between the Issuer of a credential, such as a government, health provider, workplace or school, the credential Holder (the data subject), and the Verifier (receiver of data) that is working to validate each unique data transaction. Far more secure and reliable than paper-based credentials, contract tracing forms, and traditional apps, the LAVCE and verifiable credentials can effectively reduce or eliminate fraud as all functions are supported by cryptographic blockchain solutions using the Indicio Network , the premier enterprise blockchain network for identity.
David Lucatch, CEO says it best, “Quick and easy verification for vaccine status with robust protection against fraudulent issuance is just one of many of the LAVCE’s important applications, Our communities just started opening up and it’d be a potential economic disaster if we had to collectively shut down again. We believe that it’s not enough to just say that you’re vaccinated or tested, we need a seamless, non-invasive, and privacy-respecting method for organizations to verify that individuals are immunized so that they can safely access their services…”
Sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 4:04 PM on Monday, August 16th, 2021
In an interview just over a month ago, Empower Clinics CEO Steve McAuley talked about how the Company is in full-blown growth mode that were best summarized as follows:
“Multiple opportunities have been percolating and I’m going to turn up the heat”
To this added seeing
“substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”.
Today McAuley and the team at Empower backed up those words with this announcement:
“The Company can now confirm the first new clinic launches will take place in September – location and ribbon cutting ceremonies to be announced – with rollouts of further locations continuing on a regular basis from that point forward.”
In today’s interview McAuley takes shareholders through a detailed overview of the foundation that has now been built, ready to launch and strong enough to catapult Empower into a completely new orbit. Watch this great interview. Welcome to the launch pad.
Posted by AGORACOM
at 12:15 PM on Monday, August 16th, 2021
Biotech companies, by their very nature, can often be difficult to understand for investors… but in order to understand Cardiol, all you have to know is that the firm is developing therapies for heart disease and heart failure through cannabidiols.
Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).
The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™.
CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP and THC free. (less than 10 ppm)
Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.
This week, the company passed another major milestone, moving from the OTC Markets to a U.S. listing on NASDAQ, under the symbol $CRDL – the same as its TSX symbol.
And with the COVID-19 Delta Variant running rampant through North America, Cardiol’s work has become more important than ever.
We sat down with David Elsley, Cardiol Therapeutics’ President & CEO, to discuss the uplisting…
Posted by AGORACOM-JC
at 10:56 AM on Monday, August 16th, 2021
When it comes to small-cap companies, tech-focused Datametrex AI (DM: TSXV) (D4G: FSE) (DTMXF: OTCQB) is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.
In our newest interview with Datametrex, we sit down with CEO Marshall Gunter to discuss the company’s explosive H1-2021.
Financial Highlights include:
Revenue of $29,494,191 compared to revenue of $2,763,796 (same period 2020)
Net earnings of $10,410,485 compared to ($1,590,239).
EBITDA of $12,250,211 compared to ($1,197,679).
Cash balance significantly increased to $10,555,375 from $1,971,987 end of 2020.
In this episode, Dr. Steve Thayer, Dr. Reid Robison, and Vhari Macbeth discuss the concept of the self, multiple “selves”, and how we work with “selfhood” in psychedelic therapy.
Novamind has completed the sale of its investment in the Synthesis Institute, a strategic decision that enables Novamind to focus on the expansion of its network of clinics and clinical research sites located in the U.S.
“Novamind has experienced rapid growth in its two core businesses,” said Yaron Conforti, Chief Executive Officer and Director. “We’ve established a unique and scalable business model that serves clients at our clinics and drug developers at our research sites. We are now exclusively focused on the continued growth of our clinic and contract research organization businesses, with near-term expansion into other U.S. states and an exciting pipeline of clinical trials.”
New research indicates that ketamine, in combination with light, may be able to temporarily restore our brains back to the plasticity seen in critical growth periods. More research is needed, but initial studies are promising. “Whether or not ketamine and/or flickering light could enable temporary neural plasticity in other parts of the brain, perhaps to treat language disorders or learning disabilities, is also “an intriguing possibility and would need further experiments,” Siegert added.” We look forward to further research exploring the life changing potential of ketamine.
Zoe Cormier explores the benefits and costs of psychedelic therapy models—group vs solo. Strong anecdotal evidence is provided for the group therapy model. In practice, a case can be made for both, which is why the treatment protocols available at our Cedar Psychiatry clinics include group and solo participation. You can learn more about them here.
